लोड हो रहा है...
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 w...
में बचाया:
| में प्रकाशित: | Ther Clin Risk Manag |
|---|---|
| मुख्य लेखकों: | , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Dove Medical Press
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762434/ https://ncbi.nlm.nih.gov/pubmed/26937194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S71855 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|